Amlodipine/Olmesartan

Phase 3Small molecule

RRadboud University Medical Center

Amlodipine/Olmesartan is one of 21 small molecule programs targeting Blood Pressure. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blood PressureRecruiting

Blood PressurePhase 3

Recruiting

Competition

Competitive Landscape

30 competitors in Blood Pressure

#DrugCompanyPhaseTrials

Benicar

Novartis

Phase 3

2 2

Amlodipine/Olmesartan

RRadboud University Medical Center

Phase 3

1 3

Intropin

Pfizer

Preclinical

1 4

Isoproterenol Hydrochloride

Sanofi

Preclinical

1 5

Robinul

Jazz Pharmaceuticals

Preclinical

1 6

Carbocaine

Pfizer

Preclinical

1 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Preclinical

1 9

Atropen

FFresenius Kabi Taiwan Ltd.

Preclinical

1 10

Pitressin

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Blood Pressure1 trial

Multi-Omics to Predict the Blood Pressure Response to Antihypertensives

Recruiting·RRadboud University Medical Center·Phase 4·NCT05917275·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Amlodipine/Olmesartan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amlodipine/Olmesartan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amlodipine/Olmesartan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radboud University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRadboud University Medical Center

Amlodipine/Olmesartan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Blood Pressure1 trial

References

Drug Info

Quick Facts

Related News